For research use only. Not for therapeutic Use.
Nebicapone is a selective catechol-O-methyltransferase (COMT) inhibitor, primarily used in neurological research for the treatment of Parkinson’s disease. By inhibiting COMT, nebicapone prevents the breakdown of levodopa, a precursor to dopamine, thereby increasing its bioavailability in the brain and improving motor function in Parkinson’s patients. It is studied as an adjunct therapy to enhance the effectiveness of levodopa/carbidopa treatment. Nebicapone’s ability to modulate dopamine levels makes it a promising candidate for managing motor symptoms in Parkinson’s disease while minimizing fluctuations in dopamine availability.
| Catalog Number | I008269 |
| CAS Number | 274925-86-9 |
| Synonyms | 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenylethanone |
| Molecular Formula | C14H11NO5 |
| Purity | ≥95% |
| InChI | InChI=1S/C14H11NO5/c16-12(6-9-4-2-1-3-5-9)10-7-11(15(19)20)14(18)13(17)8-10/h1-5,7-8,17-18H,6H2 |
| InChIKey | MRFOLGFFTUGAEB-UHFFFAOYSA-N |
| SMILES | C1=CC=C(C=C1)CC(=O)C2=CC(=C(C(=C2)O)O)[N+](=O)[O-] |
